关于酪氨酸激酶抑制剂治疗与慢性期慢性髓性白血病移植的若干问题
本文是一篇评论性文章,围绕已故慢性髓性白血病专家Michele Baccarani教授提出的若干问题展开讨论,内容涉及酪氨酸激酶抑制剂(TKI)治疗下持续无治疗缓解(TFR)的比例、TKI治疗失败人群的识别、异基因移植的疗效与风险,以及移植在慢性期CML治疗决策中的定位。
要点
- 接受TKI治疗的慢性期CML患者中仅小部分可能达到持续TFR,更少可能被治愈。
- 最可能TKI治疗失败者可在诊断时或开始TKI治疗后不久识别,可能需终身TKI治疗。
- 异基因移植的无白血病生存率高于TKI治疗,但移植相关死亡风险近20%(移植后1年内)。
核心结论
- 接受TKI治疗的慢性期CML患者中仅小部分可能达到持续TFR,更少可能被治愈。
- 最可能TKI治疗失败者可在诊断时或开始TKI治疗后不久识别,这些患者可能需终身TKI治疗并承受不良事件、费用和心理后果风险。
- 异基因移植的无白血病生存率远高于TKI治疗,但伴随移植相关不良事件,包括移植后1年内近20%的移植相关死亡风险,以及因慢性移植物抗宿主病等并发症导致的生活质量受损。
- 作者建议(弱推荐)在咨询不太可能通过TKI达到TFR的慢性期CML患者时,应更常考虑移植,并质疑当前是否低估了这一可能的important治疗干预。
研究设计与样本
- 本文为评论性文章,围绕已故慢性髓性白血病专家Michele Baccarani教授提出的若干问题展开讨论。
主要发现
- 接受TKI治疗的慢性期CML患者中仅小部分可能达到持续TFR,更少可能被治愈。
- 最可能TKI治疗失败者可在诊断时或开始TKI治疗后不久识别,这些患者可能需终身TKI治疗并承受不良事件、费用和心理后果风险。
- 异基因移植的无白血病生存率远高于TKI治疗,但伴随移植相关不良事件,包括移植后1年内近20%的移植相关死亡风险,以及因慢性移植物抗宿主病等并发症导致的生活质量受损。
- 与移植结局相关的受者、疾病和移植相关协变量已被以合理准确性所认识。
- 并非所有可能TKI治疗失败者都是移植候选者;在那些是候选者的患者中,医生和患者需权衡TKI治疗与移植的获益和风险。
临床怎么用
- 作者建议(弱推荐)在咨询不太可能通过TKI达到TFR的慢性期CML患者时,应更常考虑移植。
- 作者质疑当前是否低估了移植这一可能的important治疗干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this provocative commentary, we consider several questions posed by the late chronic myeloid leukaemia (CML) expert Prof. Michele Baccarani, which he challenged us to address after his death. He noted only a small proportion of people with chronic phase CML receiving tyrosine kinase-inhibitor (TKI)-therapy are likely to achieve sustained therapy-free remission (TFR) and even fewer are likely to be cured. Persons most likely to fail TKItherapy can be identified at diagnosis or soon after starting TKI-therapy. These persons are likely to need lifetime TKI-therapy with attendant risks of adverse events, cost and psychological consequences. Allogeneic transplants achieve much higher rates of leukaemia-free survival compared with TKI-therapy but are associated with transplant-related adverse events including an almost 20 percent risk of transplant-related deaths within 1 year post-transplant and a compromised quality-of-life because of complications such as chronic graft-versus-host disease. Subject-, disease- and transplant-related co-variates associated with transplant outcomes are known with reasonable accuracy. Not everyone likely to fail TKI-therapy is a transplant candidate. However, in those who candidates are physicians and patients need to weigh benefits and risks of TKI-therapy versus a transplant. We suggest transplants should be more often considered in the metric when counseling people with chronic phase CML unlikely to achieve TFR with TKI-therapy. We question whether we are discounting a possible important therapy intervention; we think so.
引用
- Baccarani M, Bonifazi F, Soverini S, et al. Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia. Leukemia. 2022. PMID: 35338251. doi:10.1038/s41375-022-01522-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。